-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCLETIS PHARMA - SELECTS FIXED-DOSE COMBINATION OF ASC48 AND ASC30 FOR CLINICAL DEVELOPMENT

Reuters·07/15/2026 10:00:53

Please log in to view news